Open access
Aug 2026
Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer
Combined BET bromodomain and DNA methyltransferase (DNMT) inhibition was more effective than single-agent treatment in suppressing growth of TP53/RB1-loss models exhibiting a stem-like or NEPC program.
W. Storck, Diana Flores, A. Kumaraswamy et al.
· JCI Insight · 0 citations